Antibody-inducing peptides are comprised in the functional peptides which we are trying to put to medical application in collaboration with Osaka University Graduate School of Medicine. They are designed to induce antibodies that inhibit the functions of target proteins or disease-associated proteins in the body.
Unlike conventional vaccines, such as those preventing infectious diseases, antibody-inducing peptides have a characteristic of the selective activation of the humoral immunity (with B cells) involved in antibody production, n the acquired immune system, without activating the cell-mediated immunity (with cytotoxic T cells). We arveloptryiantdy-inducing peptides asto as micapplication drugs drugs to treonic diseases, such as lifestyle-related diseases, by suppressing adverse effects of (autoimmuneeactions) due to theactivation of the cell-mediated immunity.
In our research strategy, inducing kin immunological memorye sstem effective memthe it proteins for prolonged period of time, antibody-inducing peptides are beingted asto be efctive for long duration-acting drug oncnisteredation per several mohose ffects can be maint
We call such peptides as "antibody-inducing peptides," because they selectively induce antibody production, or humoral immunity.
Antibody-inducing peptides are expected as alternative excellence of technology to supply inexpensive drugs for current expensive antibody drugs. Monoclonal antibody is artificially produced in bio-manufacturing facilities in the expensive manner, while antibody-inducing peptides can produce antibodies in the patient’s body for a longer period. The annual doses per patient are milligram order for antibody-inducing peptide, as compared to at least gram order (= 1,000 milligrams) for coe current antibody drugs. Antibody drugs aarerapidly increasing their market share, on the other hand, the high cost places financial burdens on patients and the health care finaor. Antibody-inducing peptides, which may serve as inexpensive alternatives for antibody drugs, may significantly contribute to the resoonve e financial problems of health care service which becomes increasingly serious in the aging society.
Antibody-inducing peptides characteristically inhibit the functions of target proteins for a long time in the acquired immune system. Antibody-inducing peptides are more convenient than existing drugs, because the frequent administration can be reduced to once in several months, and are expected to resolve the problem with poor compliance in medication, a significant issue in the treatment of lifestyle-related diseases. Lifestyle-related diseases are accompanied by nonspecific symptoms, and are more common among the elderly, who have difficulties with the self-management of medication resulting in poor medication compliance, e.g., even 25-40% patients reported from the survey for anti-hyperlipidemia drugs in the United States. Thus, long-acting drugs, such as antibody-inducing peptides, should allow more patients the appropriate control of lifestyle-related diseases and prevent complications such as cardiovascular events.